Conference Call with Alkem Laboratories Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Alkem Laboratories announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Total Revenue from Operations was Rs 34,147 million, with YoY de-growth of 0.7%. India sales were Rs 24,610 million, YoY growth of 5.7%. International sales were Rs 9,181 million, with YoY de-growth of 12.9%. Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were Rs 7,528 million, resulting in an EBITDA margin of 22.0% vs. 21.7% in Q2FY24. EBITDA increased by 0.8% YoY. R&D; expenses for the quarter were Rs 1,465 million, or 4.3% of total revenue from operations, compared to Rs 1,158 million in Q2FY24 at 3.4% of total revenue from operations. Profit before tax (PBT) before exceptional item was Rs 7,803 million, a growth of 10.6% compared to Rs 7,057 million in Q2FY24. Net Profit (after Minority Interest) was Rs 6,886 million, YoY growth of 11.0%. As per IQVIA (SSA) data, for Q2FY25, the company registered a growth of 6.3% YoY vs. the Indian Pharmaceutical Market (IPM), which grew by 7.6%. H1FY25 Financial Highlights: Total Revenue from Operations was Rs 64,465 million, with YoY growth of 0.6%. India sales were Rs 44,833 million, YoY growth of 6.0%. International sales were Rs 18,857 million, with YoY de-growth of 8.8%. Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were Rs 13,615 million, resulting in an EBITDA margin of 21.1% vs. 17.7% in H1FY24. EBITDA increased by 19.9% YoY. R&D; expenses for H1FY25 were Rs 2,722 million, or 4.2% of total revenue from operations, compared to Rs 2,360 million in H1FY24 at 3.7% of total revenue from operations. Profit before tax (PBT) before exceptional item was Rs 13,996 million, a growth of 32.2% compared to Rs 10,586 million in H1FY24. Net Profit (after Minority Interest) was Rs 12,338 million, YoY growth of 36.0%. As per IQVIA (SSA) data, for H1FY25, the company registered a growth of 7.1% YoY vs. the Indian Pharmaceutical Market (IPM), which grew by 8.2%. Vikas Gupta, CEO of Alkem, said: “We are pleased to share that the outcomes of our strategic initiatives designed to enhance profitability have proven effective. We are prioritising a high-margin product mix, aligning more effectively with market demands, and implementing cost-control measures to mitigate inefficiencies, which are supporting EBITDA margin growth. In the domestic market, our focus remains on augmenting the growth of our large brands and making strategic portfolio additions. We also see significant opportunities for growth in our emerging markets business.” Result PDF
Conference Call with Alkem Laboratories Management and Analysts on Q1FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Alkem Laboratories announced Q1FY25 results: Total Revenue from Operations was Rs 30,318 million, with YoY growth of 2.2%. India sales were Rs 20,223 million, with YoY growth of 6.4%. International sales were Rs 9,677 million, with YoY de-growth of 4.6%. Earnings before Interest, Tax, Depreciation, and Amortization (EBITDA) were Rs 6,086 million, resulting in an EBITDA margin of 20.1% vs. 13.1% in Q1FY24. EBITDA increased by 56.4% YoY. R&D; expenses for the quarter were Rs 1,257 million, or 4.1% of total revenue from operations, compared to Rs 1,202 million in Q1FY24 at 4.1% of total revenue from operations. Profit before tax (PBT) before exceptional items was Rs 6,194 million, a growth of 75.5% compared to Rs 3,529 million in Q1FY24. Net Profit (after Minority Interest) was Rs 5,452 million, with YoY growth of 90.1%. According to IQVIA (SSA—Stockist Sales Audit) data, for Q1FY25, the company registered a growth of 8.4% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 8.7%. Commenting on the Q1FY25 results, Vikas Gupta, CEO of Alkem, said, “We are happy that our efforts to improve profitability have started paying off, and we have seen a marked increase in margins during the quarter. We are committed to maximising our EBITDA margin by carefully managing our product mix, controlling costs, and taking advantage of the favourable raw material pricing environment. The domestic business is our stronghold, and we expect to build on it by furthering the growth of our large brands and bridging portfolio gaps. Simultaneously, we are also focusing on growing our business in emerging markets. During the quarter, an important development was the successful resolution of US FDA’s Form 483 at the Baddi facility. At Alkem, we remain steadfast to prioritising quality and regulatory compliance.” Result PDF